MedTrace Logo

Nonintervention Study on Peritoneal Metastasis of Stage IV Gastric Cancer

NCT03237507 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 110

Last updated 2017-08-02

No results posted yet for this study

Summary

This is a non-interventional study，aim to observe the safety and efficiency of different treatment regimen for peritoneal metastasis of Stage IV gastric cancer in the real world

Conditions

  • Stage IV Gastric Cancer With Metastasis

Interventions

DRUG

S-1

40-60mg/m\^2 bid, days 1-14, oral，every 3 weeks.

DRUG

oxaliplatin

100mg/m\^2 days 1，intravenous infusion, every 3 weeks.

DEVICE

Hyperthermic Intraperitoneal

hyperthermic intraperitoneal chemoperfusion

DRUG

Paclitaxel

intraperitoneal perfusion

Sponsors & Collaborators

  • Harbin Medical University

    lead OTHER

Principal Investigators

  • Kuan Wang · Harbin Medical University Cancer Hospital,Gastrointestinal Surgical department

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-01
Primary Completion
2019-06-01
Completion
2020-06-01
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03237507 on ClinicalTrials.gov